Article
External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.
The oncologist - 1 Jan 2011
Bellon Ellen, Ligtenberg Marjolijn J L, Tejpar Sabine, Cox Karen, de Hertogh Gert, de Stricker Karin, Edsjö Anders, Gorgoulis Vassilis, Höfler Gerald, Jung Andreas, Kotsinas Athanassios, Laurent-Puig Pierre, López-Ríos Fernando, Hansen Tine Plato, Rouleau Etienne, Vandenberghe Peter, van Krieken Johan J M, Dequeker Elisabeth
Abstract excerpt
The use of epidermal growth factor receptor-targeting antibodies in metastatic colorectal cancer has been restricted to patients with wild-type KRAS tumors by the European Medicines Agency since 2008, based on data showing a lack of efficacy and potential harm in patients with mutant KRAS tumors....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.